## Francesco Novelli

## List of Publications by Year in descending order

[^0]

Phosphoinositide Conversion Inactivates Râ€RAS and Drives Metastases in Breast Cancer. Advanced
Science, 2022, 9, e2103249.

2 Discovery of Targets for Cancer Immunoprevention. Methods in Molecular Biology, 2022, 2435, 19-33.
$0.9 \quad 1$

Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up. Frontiers in Immunology, 2022, 13, 818325.

Docking Protein p130Cas Regulates Acinar to Ductal Metaplasia During Pancreatic Adenocarcinoma Development and Pancreatitis. Gastroenterology, 2022, 162, 1242-1255.e11.

Exploring chitosan-shelled nanobubbles to improve HER2â€\%o+â€\%oimmunotherapy via dendritic cell targeting.
Drug Delivery and Translational Research, 2022, 12, 2007-2018.

IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches
6 on their protumorigenic functions. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .

7 The Clycolytic Pathway as a Target for Novel Onco-Immunology Therapies in Pancreatic Cancer.
Molecules, 2021, 26, 1642.

IL17A Depletion Affects the Metabolism of Macrophages Treated with Gemcitabine. Antioxidants, 2021, 10, 422.

9 Low Levels of Urinary PSA Better Identify Prostate Cancer Patients. Cancers, 2021, 13, 3570.
8.6
11 In pancreatic cancer, chemotherapy increases antitumor responses to tumor-associated antigens and potentiates DNA vaccination. , 2020, 8, e001071.

Computational modeling of the immune response in multiple sclerosis using epimod framework. BMC
12 Bioinformatics, 2020, 21, 550.
2.6

9

Metabolome of Pancreatic Juice Delineates Distinct Clinical Profiles of Pancreatic Cancer and Reveals
a Link between Clucose Metabolism and PD-1 + Cells. Cancer Immunology Research, 2020, 8, 493-505.

Proteomics-Based Evidence for a Pro-Oncogenic Role of ESRP1 in Human Colorectal Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 575.

Immune-Complexome Analysis Identifies Immunoglobulin-Bound Biomarkers That Predict the Response to Chemotherapy of Pancreatic Cancer Patients. Cancers, 2020, 12, 746.
3.7

6

16 The dark side of immunotherapy: pancreatic cancer. , 2020, 3, 491-520.

Integrative Analysis of Novel Metabolic Subtypes in Pancreatic Cancer Fosters New Prognostic
Biomarkers. Frontiers in Oncology, 2019, 9, 115.
2.8

32

Stromal protein 1 íig-h3 reprogrammes tumour microenvironment in pancreatic cancer. Gut, 2019, 68,
693-707.

The advanced glycation endâ€product $\langle\mathrm{i}\rangle \mathrm{N}\langle\mid \mathrm{i}\rangle\langle\mathrm{sup}\rangle \ddot{\mathrm{l}} \mu</$ sup $\rangle$ â $€$ earboxymethyllysine promotes progression
20 of pancreatic cancer: implications for diabetesâ€ $\begin{aligned} & \text { sssociated risk and its prevention. Journal of }\end{aligned}$
Pathology, 2018, 245, 197-208.

| 21 | Beta-2-glycoprotein-1 and alpha-1-antitrypsin as urinary markers of renal cancer in von Hippelâ€"Lindau patients. Biomarkers, 2018, 23, 123-130. | 1.9 | 12 |
| :---: | :---: | :---: | :---: |
| 22 | Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype. Oncolmmunology, 2018, 7, e1393596. | 4.6 | 58 |
| 23 | FAM49B, a novel regulator of mitochondrial function and integrity that suppresses tumor metastasis. Oncogene, 2018, 37, 697-709. | 5.9 | 49 |

24 Soluble stromaâ€ elated biomarkers of pancreaticÂcancer. EMBO Molecular Medicine, 2018, 10,. 56
25 Next Generation Immunotherapy for Pancreatic Cancer: DNA Vaccination is Seeking New Combo Partners. Cancers, 2018, 10, 51. ..... $3.7 \quad 21$
Pregnancy Epigenetic Signature in T Helper 17 and T Regulatory Cells in Multiple Sclerosis. Frontiers in Immunology, 2018, 9, 3075.

Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic canceradhesion, invasion, and metastasis. Journal of Hematology and Oncology, 2017, 10, 16.
31 Alpha-Enolase i ENO1 i a potential target in novel immunotherapies. Frontiers in Bioscience - Landmark, 2017, 22, 944-959.

Overcoming the lack of kinetic information in biochemical reactions networks. Performance Evaluation Review, 2017, 44, 91-102.

Protein disulfide isomerase A3â€"specific Th1 effector cells infiltrate colon cancer tissue of patients
38 with circulating antiấ "protein disulfide isomerase A3 autoantibodies. Translational Research, 2016, 171

Intra-tumoral IFN-î3-producing Th22 cells correlate with TNM staging and the worst outcomes in pancreatic cancer. Clinical Science, 2016, 130, 247-258.

```
Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a
43 potential prognostic factor for pancreatic adenocarcinoma. International Journal of Oncology, 2016,
49, 393-401.
```

Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma.
Oncolmmunology, 2016, 5, e1085147.
4.6

169
45 Alemtuzumab long-term immunologic effect. Neurology: Neuroimmunology and NeuroInflammation,
2016, 3, e194.
6.0

65
 restraining effector T cell response. Oncolmmunology, 2016, 5, el112940.
Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative
phosphorylation and induces growth arrest. Oncotarget, 2016, 7,5598-5612.

48 ATP-Binding-Cassette A1 Regulates Extracellular Isopentenyl Pyrophosphate Release and Vî39Vî́2 T-Cell Activation By Dendritic Cells. Blood, 2016, 128, 3709-3709.
1.4

0
正

Proteomic analysis of extracellular vesicles from medullospheres reveals a role for iron in the cancer progression of medulloblastoma. Molecular and Cellular Therapies, 2015, 3, 8.
0.2

19

Pharmacological Preconditioning by Adenosine A2a Receptor Stimulation: Features of the Protected
1.9

11
Liver Cell Phenotype. BioMed Research International, 2015, 2015, 1-9.

Pancreatic cancer vaccine: a unique potential therapy. Gastrointestinal Cancer: Targets and Therapy,
2015, , 1.
5.5

0

Mouse hepatocytes and LSEC proteome reveal novel mechanisms of ischemia/reperfusion damage and protection by A2aR stimulation. Journal of Hepatology, 2015, 62, 573-580.

| 55 | Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells. Oncotarget, 2015, 6, 11098-11113. | 1.8 |
| :---: | :---: | :---: |
| 56 | Class II Transactivator-Induced MHC Class II Expression in Pancreatic Cancer Cells Leads to Tumor Rejection and a Specific Antitumor Memory Response. Pancreas, 2014, 43, 1066-1072. | 1.1 |
| 57 | Chimeric Rat/Human HER2 Efficiently Circumvents HER2 Tolerance in Cancer Patients. Clinical Cancer Research, 2014, 20, 2910-2921. | 7.0 |
| 58 | Th22 cells are expanded in multiple sclerosis and are resistant to IFN-î2. Journal of Leukocyte Biology, 2014, 96, 1155-1164. | 3.3 |

Mass spectrometric analysis reveals O-methylation of pyruvate kinase from pancreatic cancer cells.
Analytical and Bioanalytical Chemistry, 2013, 405, 4937-4943.
62

Chronic hypoxia reprograms human immature dendritic cells by inducing a proinflammatory phenotype and <scp>TREM</scp>â€』 expression. European Journal of Immunology, 2013, 43, 949-966.
2.9

49

| 63 | Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions. Cancer Immunology, Immunotherapy, 2013, 62, 1249-1260. | 4.2 | 102 |
| :---: | :---: | :---: | :---: |
| 64 | Vaccination With ENO1 DNA Prolongs Survival of Genetically Engineered Mice With Pancreatic Cancer. Gastroenterology, 2013, 144, 1098-1106. | 1.3 | 104 |
| 65 | Quartz crystal microbalance with dissipation (QCM-D) as tool to exploit antigenấ ${ }^{\text {" }}$ antibody interactions in pancreatic ductal adenocarcinomadetection. Biosensors and Bioelectronics, 2013, 42, 646-652. | 10.1 | 29 |
| 66 | Early expression of the fractalkine receptor CX3CR1 in pancreatic carcinogenesis. British Journal of Cancer, 2013, 109, 2424-2433. | 6.4 | 26 |
| 67 | Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. Journal of Hematology and Oncology, 2013, 6, 67. | 17.0 | 42 |
| 68 | Three are better than one: plasminogen receptors as cancer theranostic targets. Experimental Hematology and Oncology, 2013, 2, 12. | 5.0 | 33 |
| 69 | Towards pancreatic cancer diagnosis using EIS biochips. Lab on A Chip, 2013, 13, 730. | 6.0 | 32 |

70 A self antigen reopens the games in pancreatic cancer. Oncolmmunology, 2013, 2, e24384.
$4.6 \quad 8$

Acute-Phase Protein Hemopexin Is a Negative Regulator of Th17 Response and Experimental Autoimmune
Encephalomyelitis Development. Journal of Immunology, 2013, 191,5451-5459.
0.8

28Th17 Cells in Multiple Sclerosis Express Higher Levels of JAK2, Which Increases Their SurfaceHypoxia modulates the gene expression profile of immunoregulatory receptors in human mature79 dendritic cells: identification of TREM-1 as a novel hypoxic marker in vitro and in vivo. Blood, 2011, 117,
81 Investigation of the Ovarian and Prostate Cancer Peptidome for Candidate Early Detection Markers Using a Novel Nanoparticle Biomarker Capture Technology. AAPS Journal, 2010, 12, 504-518.
83 Mass Spectrometry Analysis of the Post-Translational Modifications of $\hat{\mathrm{I}}_{ \pm}$-Enolase from Pancreatic
Ductal Adenocarcinoma Cells. Journal of Proteome Research, 2010, 9, 2929-2936.
3.766Tâ€helper 17 cells expand in multiple sclerosis and are inhibited by interferonâ $\not \hat{\imath}^{2}$. Annals of Neurology,2009, 65, 499-509.
5.3

340

85 pancreatic ductal adenocarcinomaâ€associated antigen. International Journal of Cancer, 2009, 125,
639-648.

IL-6, but not IFN-Î3, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3
Type I IFN inhibits the expansion of Th17 lymphocytes from both healthy subjects and Multiple Sclerosis
patients. FASEB Journal, 2008, 22, 1069.6.


In the absence of IGF-1 signaling, IFN-î3 suppresses human malignant T-cell growth. Blood, 2007, 109,

Iron regulates T-lymphocyte sensitivity to the IFN-Î3/STAT1 signaling pathway in vitro and in vivo. Blood, 2005, 105, 3214-3221.
$1.4 \quad 40$
99 IFN- 13 inhibits the proliferation of allergen-activated T lymphocytes from atopic, asthmatic patients byinducing Fas/FasL-mediated apoptosis. Journal of Leukocyte Biology, 2004, 76, 423-432.

The role of IL-12, IL-23 and IFN-î3 in immunity to viruses. Cytokine and Growth Factor Reviews, 2004, 15,
7.2

95

Requirement for both IL-12 and IFN-Î3 signaling pathways in optimal IFN-Î3 production by human T cells.109 Surface Expression of the IFN-î3R2 Chain Is Regulated by Intracellular Trafficking in Human T
Partial Interferonâ€̂̂3 Receptor Signaling Chain Deficiency in a Patient with Bacille Calmetteâ€GuÃ@rin andMycobacterium abscessusInfection. Journal of Infectious Diseases, 2000, 181, 379-384.
Inheritable defects in interleukinâ€d 2â€•and interferonâ€gammaâ€mediated immunity and the TH1/TH2 paradigm 5.7
in man. Allergy: European Journal of Allergy and Clinical Immunology, 1999, 54, 409-412.

112 Expression and Role of IL-15 in Post-Burn Hypertrophic Scars. Journal of Investigative Dermatology,

Functional analysis of T lymphocytes infiltrating the dermis and epidermis of post-burn hypertrophic
1.9 scar tissues. Burns, 1999, 25, 43-48.
117 Expression and role in apoptosis of the alpha- and beta-chains of the IFN-gamma receptor on human Th1and Th2 clones. Journal of Immunology, 1997, 159, 206-13.Immunology, 1996, 157, 1935-43.
119 Environmental signals influencing expression of the IFN-gamma receptor on human T cells control whether IFN-gamma promotes proliferation or apoptosis. Journal of Immunology, 1994, 152, 496-504. 0.8 ..... 58
Modulation of interferon- $\hat{1}^{3}$ receptor during human T lymphocyte alloactivation. European Journal of Immunology, 1993, 23, 1226-1231.


[^0]:    Source: https://exaly.com/author-pdf/5391468/publications.pdf
    Version: 2024-02-01

